Sichuan University

This study tests whether a cancer-killing virus, combined with chemotherapy and immunotherapy, can shrink advanced esophageal tumors enough to allow surgery. About 40 adults with initially inoperable esophageal cancer will receive the combination treatment. The goal is to improve…

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard targeted therapy. About 40 adults will receive the combination to …

This study tests whether giving low-dose radiation and immunotherapy before standard chemotherapy can help shrink tumors in people with stage II to III non-small cell lung cancer. The goal is to make surgery more effective and improve long-term outcomes. About 30 adults who have …

This study tests whether adding an immunotherapy drug (adebrelimab) and low-dose radiation to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer. About 202 adults aged 18-75 who have not had prior treatment for this stage will take part.…

This study tests whether adding low-dose radiation to standard immunotherapy and chemotherapy can shrink tumors better than standard treatment alone in people with advanced squamous cell lung cancer. About 114 participants will be randomly assigned to one of two groups. The goal …

This study tests a new treatment for people with a specific type of advanced small cell lung cancer (SLFN-11 positive). The treatment combines low-dose radiation, chemotherapy, and two drugs (sugemalimab and olaparib). The goal is to see if this combination is safe and helps cont…

This study tests whether intensive nutritional support can help patients with locally advanced esophageal cancer that cannot be surgically removed. Participants receive standard chemo-immunotherapy and are randomly assigned to either intensive enteral nutrition or standard care. …

This early safety study is testing a new combination treatment for patients with large, advanced solid tumors that have stopped responding to standard therapies. It combines two types of targeted radiation with an immunotherapy drug called tislelizumab. The main goal is to find o…